PuraPharm Corporation Limited (1498.HK)
HKD 0.55
(-3.51%)
HKD 0.55
(-3.51%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 424.77 Million HKD | -15.58% |
| 2022 | 503.15 Million HKD | -5.41% |
| 2021 | 531.95 Million HKD | 1.5% |
| 2020 | 524.11 Million HKD | -3.22% |
| 2019 | 541.53 Million HKD | -1.27% |
| 2018 | 548.47 Million HKD | 0.08% |
| 2017 | 548.02 Million HKD | 109.93% |
| 2016 | 261.04 Million HKD | 108.12% |
| 2015 | 125.43 Million HKD | -31.34% |
| 2014 | 182.69 Million HKD | -2.92% |
| 2013 | 188.19 Million HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 377.69 Million HKD | -2.88% |
| 2023 Q2 | 454.84 Million HKD | -9.6% |
| 2023 FY | 424.77 Million HKD | -15.58% |
| 2023 Q4 | 424.77 Million HKD | -6.61% |
| 2022 FY | 503.15 Million HKD | -5.41% |
| 2022 Q4 | 503.15 Million HKD | 10.37% |
| 2022 Q2 | 455.87 Million HKD | -14.3% |
| 2021 FY | 531.95 Million HKD | 1.5% |
| 2021 Q4 | 531.95 Million HKD | 1.21% |
| 2021 Q2 | 525.62 Million HKD | 0.29% |
| 2020 Q4 | 524.11 Million HKD | 18.05% |
| 2020 Q2 | 443.98 Million HKD | -18.01% |
| 2020 FY | 524.11 Million HKD | -3.22% |
| 2019 FY | 541.53 Million HKD | -1.27% |
| 2019 Q4 | 541.53 Million HKD | -6.33% |
| 2019 Q2 | 578.12 Million HKD | 5.4% |
| 2018 Q4 | 548.47 Million HKD | 3.86% |
| 2018 FY | 548.47 Million HKD | 0.08% |
| 2018 Q2 | 528.07 Million HKD | -3.64% |
| 2017 FY | 548.02 Million HKD | 109.93% |
| 2017 Q4 | 548.02 Million HKD | 1.96% |
| 2017 Q2 | 537.48 Million HKD | 105.89% |
| 2016 Q4 | 261.04 Million HKD | 9.98% |
| 2016 FY | 261.04 Million HKD | 108.12% |
| 2016 Q2 | 237.36 Million HKD | 89.24% |
| 2015 FY | 125.43 Million HKD | -31.34% |
| 2015 Q4 | 125.43 Million HKD | -37.27% |
| 2015 Q2 | 199.96 Million HKD | 9.45% |
| 2014 FY | 182.69 Million HKD | -2.92% |
| 2014 Q4 | 182.69 Million HKD | 0.0% |
| 2013 FY | 188.19 Million HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -6137.446% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 87.522% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -252.77% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 7.849% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -87121.766% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -108.078% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -44.469% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -27.244% |
| SSY Group Limited | 3.37 Billion HKD | 87.411% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -218.402% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 43.317% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.505% |